Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-course versus standard-course R-CHOP followed by radiotherapy for localized low-risk diffuse large B-cell lymphoma
ChiCTR1800018708Phase 3Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Oct 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: 5-year disease-free survival. Started Oct 2018; status: recruiting.
02
Drugs
rituximabcyclophosphamidedoxorubicinvincristineprednisone
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR1800018708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800018708.